Tenofovir Disoproxil Fumarate in Patients with HIV and Lamivudine-Resistant Hepatitis B Virus
- 9 January 2003
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (2) , 177-178
- https://doi.org/10.1056/nejm200301093480218
Abstract
Mutations in the YMDD (tyrosine, methionine, aspartate, aspartate) motif of the DNA polymerase resulting in phenotypic hepatitis B virus (HBV) resistance to lamivudine monotherapy have been observed after two years in 50 percent of patients coinfected with the human immunodeficiency virus (HIV).1 Adefovir dipivoxil has been shown to be effective for lamivudine-resistant HBV infection in HIV-coinfected patients.2 Tenofovir disoproxil fumarate, a nucleotide reverse-transcriptase inhibitor, is active against HIV and has in vitro activity against wild-type and lamivudine-resistant HBV.3,4Keywords
This publication has 3 references indexed in Scilit:
- Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot studyThe Lancet, 2001
- Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L‐FMAU, DAPD, penciclovir and lobucavirJournal of Viral Hepatitis, 2000
- Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patientsHepatology, 1999